Board of Directors
The Leadership behind Restorative Therapies
James “Jim” Janicki
Jim Janicki is a senior executive with deep experience in the medical device and life science industries where he has maximized value creation by delivering significant global healthcare improvements.
Jim has held positions running global clinical diagnostic and medical device businesses and has turned around businesses including the transformation of an 8% year over year declining revenue to 20+% revenue growth with significant operating margin improvements. He has held positions at some of the most accomplished companies in the world, including Becton Dickinson, GE, Dow Chemical, Thermo Fisher, Sun Microsystems, Life Technologies, Affymetrix, and he has experience as a corporate officer in publicly traded companies before focusing on early-stage technology companies and lower middle market private equity companies. Jim knows how to work at every scale of business.
Jim is a registered professional engineer; he is also a certified Lean Sigma Master Black Belt efficiency expert, and has served as the Chairman of the Industrial and Professional Advisory Council for the College of Engineering at The Pennsylvania State University where he also served as the commencement speaker to the 2010 graduating class. He previously served as the Board Chair for Healthcare Access Maryland, which is a $20M+ nonprofit of 220+ people in Baltimore, that is focused on providing healthcare access to the most vulnerable in society across the state of Maryland. Jim is currently the President & CEO of Restorative Therapies Inc., and he is an inventor on four patents and holds a BS in Chemical Engineering from The Pennsylvania State University, and an MBA from Western Michigan University, and is a graduate of the Executive Strategic Marketing program at the Stanford Graduate School of Business.
Rich Kollender
Mr. Kollender has more than 30 years of experience in the healthcare industry. Since 2024, he has served as the Chief Executive Officer and as a Director of Reaction Biology Corporation, a global contract research organization serving clients in the biotech, pharmaceutical and academic settings. From 2022-2024, he served as the Chief Business Officer and Chief Financial Officer of Reaction Biology Corporation. Prior to Reaction Biology, Mr. Kollender served as the President and Chief Financial Officer of Strongbridge Biopharma (Nasdaq: SBBP) from 2019 until it was acquired by Xeris Biopharma, Inc. (Nasdaq: XERS) in late 2021, and previously served as a director of Strongbridge Biopharma from 2015 until his executive-level appointment in 2019. From 2003, he served first as a Principal and then Partner of Quaker Partners Management, LP, a healthcare venture capital and growth venture firm. In addition, from 2016 through 2018, he served as Chief Business Officer and Chief Financial Officer of Rapid Micro Biosystems, a Quaker Partners’ portfolio company, where he played a key role in the business expansion and adoption of the company’s Growth Direct™ System. Previously, he held positions in sales, marketing and worldwide business development at GlaxoSmithKline (GSK) and served as investment manager at its corporate venture capital arm, S.R. One.
He began his career as a certified public accountant initially with KPMG. He currently serves as Chairman of the board of directors for Restorative Therapies. He also serves on the board of directors for Rapid Micro Biosystems (Nasdaq: RPID) and Ocugenix, Inc. and as an adjunct faculty member at Lehigh University. He previously served on the board of directors of Insmed, NuPathe, Inc., and Celator Pharmaceuticals, Inc, in addition to several other privately held companies. He holds an M.B.A. and a certificate degree in the graduate program in health administration and policy, both from the University of Chicago and a B.A. in accounting from Franklin and Marshall College.
Craig Matturro
Craig Matturro joined 1315 Capital in 2016 after two years as an Analyst in the Investment Banking Group of Leerink Partners, LLC, where he worked on multiple M&A and private placement engagements for small to mid-cap public and private companies across all healthcare subsectors.
During his time at 1315 Capital, Craig went on secondment to serve as Director of Business Development for 1315 Capital portfolio company, JDS Therapeutics, where he led the divesture of the Company’s Nutrition21 division to Everwell Health, as well as the acquisition of patented nutraceutical assets by the Company’s Bonafide Health division (acquired by Pharmavite).
Craig currently serves on the board of Restorative Therapies, Triple Ring Technologies, SciSafe and Spineology. He is a board observer for Onkos Surgical, and previously was a board observer for Solsys Medical (acquired by Misonix) and Centurion Service Group (acquired by TRIMEDX).
Craig received a BSc from Carnegie Mellon University in Business Administration – Concentration in Finance with University Honors, and a minor in Engineering Studies.
Todd Cushman
Mr. Cushman began his career in medical devices at American Hospital Supply Corporation (now Baxter, Inc.) in sales and marketing. In 1984, he founded Acumed, Inc., a medical manufacturing and distribution company which was acquired by Medtronic, Inc. in 1999. From 1999 - 2004, Mr. Cushman served as Group Director for Medtronic’s Neurosurgical Division.
In 2004, Mr. Cushman was a founding member of Bioness, Inc., a medical technology company specializing in neuro rehabilitation and implantable products for pain management. At Bioness, he held various commercial and operational roles from 2004 – 2012 and served as President and CEO from 2013 until the company was acquired by Bioventus, Inc., in 2021. During his tenure at Bioness, Mr. Cushman work closely with the Chairman of the Board, renowned medical entrepreneur Alfred Mann, to develop Bioness and acquire, sell and license medical device IP, technologies and companies in the Mann Group for over $9B. He brings with him extensive experience in executive leadership, product development, global operations, mergers and acquisitions. From 2021 – 2023 Mr. Cushman was an executive at Neuronetics, a Transcranial Magnetic Stimulation manufacturer to address major depressive disorder. In 2025, Mr. Cushman successfully led an initiative to reacquire the assets of Bioness from Bioventus and now serves as the CEO of Bioness Medical, Inc.
Mr. Cushman has a BA from Brown University and an MBA from the Marshall School of Business at the University of Southern California. Mr. Cushman serves on the Boards of Directors for Voiceitt and the Alfred Mann Institute at the Technion, Israel Institute of Technology.
Matt Reber
Matthew joined 1315 Capital as Partner in 2017, bringing extensive healthcare investing experience across debt and equity transactions. Prior to joining 1315 Capital, he spent 9 years at HealthCare Royalty Partners, most recently as a Managing Director. He currently serves on the board of Experic, Medivant Healthcare, Primrose Bio, ProSciento, and SciSafe, and previously served on the board of Reaction Biology (acquired by Cobepa) and Verogen (acquired by QIAGEN). Matthew also serves on the Board of Directors of Life Sciences Pennsylvania.
Matthew has over two decades of growth stage investing experience with a focus on the specialty pharmaceutical, pharmaceutical outsourcing, and medical technology sectors. Prior to HealthCare Royalty Partners, Matthew worked at Accretive LLC and Paul Capital Partners. Earlier in his career, he worked as a principal investor focused on the healthcare industry at Oak Hill Capital Partners and J.H. Whitney & Co. Matthew started his career as a healthcare investment banker at Morgan Stanley. Matthew has worked on over $1 billion in healthcare financing over the course of his career.
Matthew received a BSc in Engineering, magna cum laude, from Princeton University, an MBA with honors from The Wharton School of the University of Pennsylvania, and a Master of Biotechnology degree from the University of Pennsylvania.
